CytoDyn Inc.
OTC:CYDY
0.18 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | CytoDyn Inc. |
Symbool | CYDY |
Munteenheid | USD |
Prijs | 0.18 |
Beurswaarde | 167,607,360 |
Dividendpercentage | 0% |
52-weken bereik | 0.15 - 0.48 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Antonio Migliarese CPA |
Website | https://www.cytodyn.com |
An error occurred while fetching data.
Over CytoDyn Inc.
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)